CJC-1295 vs Ipamorelin
Two growth-hormone-axis peptides that are usually combined rather than compared. CJC-1295 is a GHRH analog; ipamorelin is a selective ghrelin/GHS-R agonist.
| CJC-1295 | Ipamorelin | |
|---|---|---|
| Class | GHRH analog (releasing hormone) | Ghrelin / GHS-R1a agonist (GH secretagogue) |
| Action | Increases the amplitude of GH pulses | Triggers GH release with minimal cortisol or prolactin |
| Cadence | Longer-acting, especially the DAC version | Short-acting; often dosed alongside CJC-1295 |
| Selectivity | Acts via the GHRH receptor | Clean side-effect profile among GHRP-class peptides |
Lean toward CJC-1295 when
- You want to amplify natural GH pulses
- A longer dosing interval is preferred (DAC)
Lean toward Ipamorelin when
- You want a clean ghrelin-pathway GH release
- Minimal cortisol and prolactin impact matters
Verdict
These are complementary, not competing. The GHRH analog and the GH secretagogue act on different pathways and are typically dosed together (the 'CJC/Ipa stack') for a synergistic GH pulse. Both are investigational; educational only.
Not medical advice
Information on DoseVault is for educational purposes only and is not a substitute for medical advice, diagnosis, or treatment from a qualified healthcare provider.